- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: L04AC01 | RO-24-7375 | Ro-247375 | Zenapax®
daclizumab is an approved drug (FDA FDA (1997), EMA (1999))
Compound class: Antibody
Comment: Daclizumab is a monoclonal antibody binding to the α subunit (CD25) of the high-affinity interleukin-2 receptor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
An advanced version of daclizumab, with identical primary sequence, but which is differentially gylcosylated, called daclizumab beta (BIIB019, DAC HYP) has been developed for subcutaneous administration. Daclizumab beta's alternate glycosylation pattern changes its binding to Fc receptors and reduces its propensity to induce complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M et al.. (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N Engl J Med, 373 (15): 1418-28. [PMID:26444729]
2. Queen CL, Schneider WP, Selick HE. (1997)
Genetic engineering; complementarity zones.
Patent number: US5693761. Assignee: Protein Design Labs, Inc.. Priority date: 28/12/1988. Publication date: 02/12/1997.
3. Tran JQ, Othman AA, Mikulskis A, Wolstencroft P, Elkins J. (2016)
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Clin Pharmacol, 8: 9-13. [PMID:26929672]